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Abstract
Background: Radiotherapy (RT) in combination with androgen deprivation therapy (ADT) for prostate cancer (PCa)
carries a risk of gastrointestinal (GI) and genitourinary toxicity, which might affect the quality of life (QoL). The
purpose of this study was to assess the QoL in patients with PCa before, during and after radiotherapy (RT) and to
compare the QoL 1 year after RT to a normal population.
Methods: The QoL was evaluated prospectively by the self-administered questionnaire SF-36 in 87 patients with
PCa. The SF-36 was completed before RT (baseline), at start of RT, at end of RT and 1 year after RT. A mixed model
analysis was used to determine the changes in QoL at each time point compared to baseline. The patients’ QoL 1
year after RT was compared to a normal population consisting of 462 reference subjects matched on age and
education.
Results: One year after RT, patients reported significantly less pain and significantly fewer limitations due to their
physical health compared to baseline. Compared to the normal population, patients reported significantly less pain
1 year after RT. However, patients also reported significantly less vitality, worse mental health as well as significantly
more limitations due to physical and mental health 1 year after RT compared to the normal population.
Conclusions: In this study, patients with PCa did not experience significant impairment in the QoL 1 year after RT
compared to baseline. However, patients reported significantly worse mental health before, during and 1 year after
RT compared to the normal population.
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Background
Radiotherapy (RT) in combination with androgen
deprivation therapy (ADT) is an established treatment
for prostate cancer (PCa). Two large randomised trials
have shown that RT in combination with ADT results in
significantly improved overall survival and PCa-specific
survival in patients with locally-advanced PCa compared
to ADT alone [1, 2].
The introduction of image guided intensity modulated
radiotherapy (IG-IMRT) has resulted in decreased tox-
icity due to higher accuracy of the dose delivery [3].
However, prospective longitudinal investigations of the
QoL following new radiation techniques such as IG-
IMRT are few. Retrospective analyses of QoL are biased
by the time delay and often baseline values are not taken
into account [4].
We have performed a prospective analysis of the urin-
ary, gastrointestinal (GI) and sexual symptoms as well as
the QoL before, during and after IG-IMRT in a cohort
of 87 patients with PCa. The toxicity results have been
published previously [5]. Here, we report the changes in
QoL at the start of RT, at the end of RT and 1 year after
RT compared to baseline. Furthermore, we compare the
patients’ QoL 1 year after RT to a normal population
matched on age and education.
Methods and materials
Patients
A total of 87 consecutive patients with PCa referred to
curative RT at the Department of Oncology at Rigshospi-
talet in Copenhagen, Denmark were included in the study.
Information about patient and disease characteristics was
obtained from the patient records. The cohort has been
described previously [5]. Patient and disease characteris-
tics are found in Table 1. The median age was 67 (range
50–75). The median prostate specific antigene (PSA) level
was 11 ng/ml (range 3.1–91), and 75 % of the patients had
a T-stage of T2c or higher. Seventy-three patients (84 %)
had high risk disease according to the d’Amico classication
[6], and the remaining 14 patients (16 %) had intermediate
risk disease. Twenty-one patients (24 %) had one or more
comorbidities with obesity, hypertension and chronic ob-
structive pulmonary disease as the most frequent. There
were no signs of metastatic disease in any of the patients
based on a CT of the abdomen and a bone scintigraphy.
All patients received neo-adjuvant and concomitant
androgen deprivation therapy (ADT). The 73 patients
with high risk disease received ADT for 3 years while
the 14 patients with intermediate risk disease received
ADT for 6 months.
Radiotherapy
The radiotherapy has been described in details previ-
ously [7]. In brief, the RT was delivered with a single
beam rotational technique (VMAT - RapidArc®, Varian
Medical Systems, Palo Alto, US). For RT planning, three
fiducial markers were implanted in the prostate through
the rectum under ultrasound guidance. The CTV was
defined as the prostate and, if present, extracapsular
tumor. The proximal 2 cm of the seminal vesicles (SM)
were included in the CTV if the risk of SM involvement
exceeded 10 % [8]. The PTV margin was 5 mm in the
right-left and anterior-posterior plane and 7 mm in the
superior-inferior plane.
Image registrations and plans were based on ICRU
guidelines and performed with the Eclipse treatment
planning system (Varian Medical Systems, Palo Alto,
CA, US).
The dose was 78 Gy (2 Gy pr. fraction, 5 fractions pr.
week).
Questionnaire
We used a combination of two existing questionnaires.
The quality of life was measured with the validated Danish
version of SF-36 [9]. The toxicity was measured with the
validated PCa-specific Prostate Cancer Symptom Scale
(PCSS) questionnaire [10].
SF-36 consists of 36 questions about physical and
mental health. Based on the responses eight scales are
created. Four of the scales measure the physical function:
Physical Functioning, Role Physical - role limitations due
to physical problems, Bodily pain and General Health.
Another four scales measure the mental function: Vitality,
Table 1 Patient and disease charateristics
Categorical characteristic No. patients n = 87 Percent
T-stage
≤ T2a 17 19
T2b 5 6










GnRH agonist 86 99
Antiandrogen 1 1
Continuous characteristic Median Range
PSA (ng/ml) 11 3.1–91.0
Age (yr) 67 50–75
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Social Functioning, Role Emotional – role limitations due
to emotional problems and Mental Health. Each scale is
scored from 0 to 100 with higher scores indicating better
function. A change in score of 10 points or more is gener-
ally considered clinically significant [11]. The physical and
mental scales are furthermore transformed into two sum-
marized measures: the Physical Component Scale (PCS)
and the Mental Component Scale (MCS).
The PCSS contains questions about specific urinary,
GI and sexual symptoms. The questions are answered
on a linear scale from 0 to 10, where 0 indicates “no
problems” and 10 indicates a “high degree of problems”.
In the present analysis we used the following three ques-
tions from the PCSS, “Do you have any urinary/GI/sexual
bother?” in order to determine the impact of urinary, GI
and sexual bother on the SF-36 scores.
The questionnaires were completed before RT (base-
line), at the start of RT, at the end of RT and 1 year after
RT. Of the 87 patients, 84 (97 %) completed the question-
naire at baseline, 80 (92 %) completed the questionnaire at
the start of RT, 77 (89 %) completed the questionnaire at
the end of RT and 77 (89 %) completed the questionnaire
1 year after RT.
For each of the patients who completed the final ques-
tionnaire, six reference subjects matched on age and
education were randomly chosen from a normal popula-
tion data set, which contains SF-36 scores from approxi-
mately 3000 Danish individuals.
Statistics
A mixed model analysis of repeated measurements was
used to determine the mean changes in SF-36 scores at
the start of RT, at the end of RT and 1 year after RT
compared to baseline. The following covariates were ap-
plied in the analysis: age, smoking, comorbidity, the use
of ADT, urinary bother, GI bother and sexual bother.
The Mann-Whitney test was used to compare the pa-
tients’ SF-36 scores 1 year after RT to the normal popu-
lation’s SF-36 scores. For the normally distributed scales
PCS and MCS an independent-samples T test was used.
All analyses were performed with SPSS v. 19.0.
Results
QoL scores
Table 2 lists the mean changes in SF-36 scores at the
start of RT, at the end of RT and 1 year after RT com-
pared to baseline. Furthermore, the impact of the covari-
ates is listed. For the continuous variables age, urinary
bother, GI bother and sexual bother the results indicate
the mean change in SF-36 score per one unit increase in
the variables.
The only clinically significant changes (change >10
points) were observed in the physical domain. Patients
experienced significantly less pain and significantly fewer
limitations due to physical health both at the start of RT
and at the end of RT compared to baseline. However,
there was a significant decrease in the physical function-
ing at the end of RT and 1 year after RT with mean
changes of −3.8 (−6.7; −0.9) and −3.6 (−6.5; −0.7), re-
spectively. The PCS increased significantly at the start of
the RT compared to baseline but no significant changes
were observed at the end of RT or 1 year after RT.
In the mental domain, the mental health increased sig-
nificantly at the start of RT and 1 year after RT with
mean changes of 5.1 (1.5;8.8) and 6.3 (2.6;10.0), respect-
ively. Accordingly, the MCS increased significantly 1
year after RT compared to baseline.
Comorbidity was associated with a significant deterior-
ation in the physical functioning and general health
scores with mean changes of −7.0 (−0.3; −13.8) and −8.4
(−1.0; −15.8), respectively.
Increasing urinary bother was associated with de-
creased QoL in eight of the 10 scales, whereas increasing
GI bother was associated with decreased QoL in five
scales. Finally, increasing sexual bother was associated
with decreased QoL in one scale.
Comparison with the normal population
The mean SF-36 scores with 95 % confidence intervals
for patients and the normal population are shown in
Figs. 1 and 2. The SF-36 scores for the normal popula-
tion are displayed throughout the entire study period for
comparison although the values represent one measure-
ment only corresponding to 1 year after RT.
Table 3 compares the SF-36 scores between the 77 pa-
tients who completed the questionnaire 1 year after RT
and the normal population consisting of 462 reference
subjects. The normal population reported a significantly
higher mental QoL in terms of more vitality, fewer limi-
tations due to mental health, better mental health and
finally a higher MCS score. Furthermore, the normal
population reported significantly fewer limitations due
to physical problems. Oppositely, patients reported sig-
nificantly less pain 1 year after RT compared to the nor-
mal population.
Discussion
In this study, we investigated the changes in QoL in pa-
tients with PCa following IG-IMRT. The QoL was evalu-
ated prospectively with the use of a self-administered
questionnaire and the impact of various factors on the
QoL was determined. Furthermore, we compared the
QoL 1 year after RT to the QoL of a normal population
matched on age and education.
The results in this study display a rather complex pat-
tern of changes in the QoL during and after RT. Overall,
we did not observe any clinically significant impairment
in the QoL 1 year after RT compared to baseline. This is
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Table 2 Estimated changes in SF-36 scores from the start of RT, the end of RT and 1 year after RT compared to baseline are listed on the left. The impact of the covariates on
the scores is listed on the right
Scale Time Covariates
Mean change from baseline (95 % CI) Mean change (95 % CI)
Start RT End RT 1 year after RT Age Comorb. Smok. ADT Urinary bother GI bother Sexual bother
Physical functioning −0.7 (−3.6;2.2) −3.8 (−6.7; −0.9) −3.6 (−6.5; −0.7) −0.2 (−0.7;0.3) −7.0 (−13.8; −0.3) −0.5 (−7.8;6.8) −2.1 (−7.7;3.5) −0.6 (−1.1; −0.1) 0.1 (−0.6;0.7) 0.2 (−0.2;0.6)
p = 0.638 p = 0.010* p = 0.015* p = 0.387 p = 0.041* p = 0.897 p = 0.464 p = 0.014* p = 0.865 p = 0.357
Role physical 13.3 (4.0;22.6) 1.5 (−7.9;11.0) 11.4 (2.0;20.8) −0.2 (−1.4;1.0) −7.2 (−22.8;8.4) −1.2 (−18.1;15.8) −6.8 (−24.5;10.9) −3.3 (−4.8; −1.9) −1.0 (−2.9;1.0) 0.1 (−1.1;1.3)
p = 0.005* p = 0.754 p = 0.018* p = 0.741 p = 0.362 p = 0.890 p = 0.450 p < 0.001* p = 0.320 p = 0.873
Bodily pain 11.9 (6.1;17.7) 0.0 (−5.9;5.8) 11.4 (5.5;17.3) −0.2 (−0.8;0.4) 0.8 (−7.4;9.1) −2.6 (−11.6;6.3) 2.1 (−8.7;12.9) −1.4 (−2.3; −0.5) −2.0 (−3.2; −0.9) 0.0 (−0.7;0.7)
p < 0.001* p = 0.990 p < 0.001* p = 0.558 p = 0.840 p = 0.562 p = 0.698 p = 0.002* p = 0.001* p = 0.987
General health 0.6 (−2.5;3.8) −2.0 (−5.2;1.2) −3.6 (−6.8; −0.3) 0.5 (0.0;1.1) −8.4 (−15.8; −1.0) 0.4 (−7.6;8.3) −5.7 (−11.9;0.6) −0.6 (−1.1;0.0) −1.0 (−1.7; −0.3) 0.1 (−0.3;0.5)
p = 0.687 p = 0.222 p = 0.031* p = 0.071 p = 0.026* p = 0.931 p = 0.075 p = 0.040* p = 0.004* p = 0.588
PCS 2.1 (0.5;3.7) −1.1 (−2.7;0.5) 0.7 (−0.9;2.3) −0.1 (−0.3;0.2) −2.0 (−5.3;1.3) 0.5 (−3.0;4.1) −1.7 (−4.7;1.3) −0.5 (−0.8; −0.3) −0.4 (−0.7;0.0) 0.2 (0.0;0.4)
p = 0.008* p = 0.181 p = 0.392 p = 0.584 p = 0.225 p = 0.763 p = 0.270 p < 0.001* p = 0.032* p = 0.113
Vitality 2.9 (−1.0;6.9) −4.4 (−8.4; −0.4) 1.3 (−2.7;5.3) 0.6 (−0.1;1.3) −7.3 (−16.5;1.8) −5.5 (−15.4;4.4) 0.1 (−7.6;7.8) −1.1 (−1.7; −0.4) −1.0 (−1.8; −0.1) −0.2 (−0.8;0.3)
p = 0.144 p = 0.030* p = 0.517 p = 0.087 p = 0.113 p = 0.271 p = 0.979 p = 0.001* p = 0.028* p = 0.378
Social functioning 3.0 (−0.9;6.9) −2.3 (−6.3;1.7) 3.7 (−0.3;7.7) 0.4 (−0.2;0.9) −4.8 (−11.6;2.1) 2.6 (−4.9;10.0) 4.9 (−2.8;12.6) −0.5 (−1.1;0.1) −1.3 (−2.1; −0.5) −0.3 (−0.8;0.2)
p = 0.134 p = 0.261 p = 0.068 p = 0.171 p = 0.170 p = 0.495 p = 0.210 p = 0.132 p = 0.003* p = 0.240
Role emotional 4.6 (−3.2;12.5) −0.1 (−8.1;7.8) 2.1 (−5.8;10.1) 0.3 (−0.8;1.3) −6.6 (−20.4;7.3) −4.4 (−19.4;10.6) −2.2 (−17.3;12.9) −1.4 (−2.7; −0.2) −0.9 (−2.6; −0.2) −0.8 (−1.8;0.2)
p = 0.248 p = 0.972 p = 0.598 p = 0.597 p = 0.348 p = 0.565 p = 0.773 p = 0.028* p = 0.266 p = 0.099
Mental health 5.1 (1.5;8.8) 2.0 (−1.7;5.7) 6.3 (2.6;10.0) 0.3 (−0.2;0.8) −5.7 (−12.7;1.3) −7.1 (−14.7;0.4) 2.8 (−4.4;9.9) −0.8 (−1.4; −0.2) −0.6 (−1.4;0.2) −0.3 (−0.8;0.1)
p = 0.006* p = 0.282 p = 0.001* p = 0.242 p = 0.107 p = 0.065 p = 0.445 p = 0.014* p = 0.129 p = 0.148
MCS 1.7 (−0.3;3.8) 0.1 (−2.0;2.1) 2.1 (0.0;4.1) 0.3 (0.0;0.5) −2.8 (−6.6;1.0) −2.6 (−6.7;1.5) 1.4 (−2.5;5.4) −0.3 (−0.7;0.0) −0.4 (−0.9;0.0) −0.3 (−0.6;0.0)
p = 0.091 p = 0.931 p = 0.047* p = 0.072 p = 0.149 p = 0.208 p = 0.473 p = 0.052 p = 0.055 p = 0.026*
RT Radiotherapy
PCS Physical Component Scale












in line with previously published results [12, 13]. How-
ever, it is worth noticing that the physical functioning
and general health decreased significantly 1 year after
RT, even though the decreases were small (<5 points)
and not considered clinically significant. In contrast, pa-
tients reported significantly fewer limitations due to phys-
ical problems and significantly less pain at the start of RT
and 1 year after RT compared to baseline (change >10
points). The increase in QoL at the start of RT might be
explained by a concept called benefit finding. Benefit find-
ing refers to the fact that stressful events such as serious
illness can result in a new more positive attitude and
appreciation of ones own strength [14].
The patients’ QoL 1 year after RT was significantly dif-
ferent from the normal population in six of the 10 scales.
In the physical domain, patients reported significantly
less pain 1 year after RT compared to the normal popu-
lation. Mols et al. [15] compared PCa survivors with a
normal population and reported similar result for pa-
tients treated with radical prostatectomy, RT and watch-
ful waiting. The exact reason for the lower degree of
pain in patients with PCa following treatment is uncer-
tain. We do not know the level of pain in the patients
before they were diagnosed with PCa. It may have been
comparable to the level observed 1 year after RT and as
such lower than the level of pain in the normal popula-
tion. Patients with PCa who are treated with RT are
positively selected, since they must be without disabling
comorbidity and have a remaining life expectancy of
more than 10 years. As a consequence, they might have
Fig. 1 The graphs show the five scales in the physical domain with mean scores and 95 % confidence intervals for patients (solid line) at baseline,
at the start of RT, at the end of RT and 1 year after RT as well as the mean scores for the normal population (dashed line)
Sveistrup et al. Radiation Oncology  (2016) 11:117 Page 5 of 8
less comorbidity than the normal population, and this
might translate into less pain.
Conversely, patients reported significantly worse men-
tal health 1 year after RT compared to the normal popu-
lation. The graphs in Fig. 2 illustrate that the SF-36
scores in the mental domain are lower in patients than
in the normal population at all times, including baseline.
Again, we have no information about the patients’ men-
tal QoL before they were diagnosed with PCa, but it is
likely that the mental QoL has deteriorated as a conse-
quence of the psychological distress associated with the
diagnosis of cancer [16]. Furthermore, most patients had
commenced ADT before they completed the baseline
questionnaire. Therefore, the lower mental QoL in pa-
tients at baseline might be caused by the diagnosis of
cancer and the use of ADT, or a combination of both.
Sanda et al. [17] demonstrated that vitality was lower in
patients who received ADT and that this effect persisted
for up to 2 years despite the fact that the majority of pa-
tients received ADT for less than 1 year. This might also
be the reason why the use of ADT did not have an im-
pact on any of the SF-36 scores in our study. Further-
more, there was no significant difference in the QoL 1
year after RT between high risk patients (3 years of
ADT) and intermediate risk patients who no longer re-
ceived ADT 1 year after RT (results not shown).
We also determined the impact of urinary, GI and sex-
ual bother on the QoL. Increasing urinary and GI bother
were associated with decreased QoL in several scales.
Clark et al. [18] also evaluated the impact of symptoms
Fig. 2 The graphs show the five scales in the mental domain with mean scores and 95 % confidence intervals for patients (solid line) at baseline,
at the start of RT, at the end of RT and 1 year after RT as well as the mean scores for the normal population (dashed line)
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on SF-36 scores and found similar results. As a conse-
quence, further reduction of the urinary and GI toxicity
following RT for PCa might prove beneficial to the pa-
tients’ QoL. Oppositely, increasing sexual bother was
only associated with a worse MCS score indicating an
overall small impact of sexual bother on the QoL.
Comorbidity was associated with a significant deterior-
ation in two of the five physical scales. The fact that co-
morbidity only seemed to affect the patients’ physical
functioning and general health probably reflects the ra-
ther low level of comorbidity in patients with PCa who
are treated with RT.
This study has some limitations. The patients were
only followed for 1 year after RT. The results might
change after longer follow-up, especially since the tox-
icity might develop further even after 1 year after RT.
Furthermore, the number of patients in this study was
relatively low, which to some degree affects the reliabil-
ity of the findings.
Conclusion
This study demonstrates that IG-IMRT does not lead to
clinically significant deteriorations in the QoL 1 year
after RT. Compared to a normal population, patients
reported significantly less pain which might reflect the
positive selection of patients with PCa treated with radi-
ation. However, we also found that patients reported sig-
nificantly worse mental health before, during and 1 year
after RT compared to the normal population, which in
addition to the radiation might be a result of both the
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